Iridex Corporation will release Q2 2025 financial results on August 12, 2025, with a conference call at 2 PM PT.
Quiver AI Summary
Iridex Corporation, a leader in laser-based medical systems for treating glaucoma and retinal diseases, announced that it will release its financial results for the second quarter of 2025 and provide a business update on August 12, 2025, after market close. A conference call, beginning at 2:00 p.m. PT / 5:00 p.m. ET, will follow the announcement, and investors can participate by dialing a specified number with a passcode. The call will also be available via a live and recorded webcast on the company's website. Iridex is known for its MicroPulse® technology that offers safe and effective laser treatments, and its products are sold across the U.S. and in over 100 countries through various channels.
Potential Positives
- Iridex Corporation is positioned as a leader in the ophthalmology market, which enhances its credibility and appeal to investors.
- The announcement of a financial results release and business update indicates transparency and engagement with investors.
- The use of proprietary MicroPulse® technology highlights the company's commitment to innovative treatments, potentially improving patient outcomes and setting the company apart from competitors.
- The planned conference call provides an opportunity for investor interaction and accessibility to company updates, which can foster trust and confidence in the company's leadership.
Potential Negatives
- Failure to provide financial results ahead of the scheduled release may lead to investor concern regarding the company's performance and transparency.
- The announcement lacks specific details regarding any upcoming product launches or updates, which could signal stagnation in innovation.
- Notably absent are any updates on regulatory approvals or market expansion efforts, which are crucial for investor confidence in growth prospects.
FAQ
When will Iridex announce its Q2 2025 financial results?
Iridex plans to release its Q2 2025 financial results on August 12, 2025.
How can investors join the Iridex conference call?
Investors can join the conference call by dialing +1-888-596-4144 with the passcode: 2197032.
What is the main product focus of Iridex Corporation?
Iridex specializes in laser-based medical systems for treating glaucoma and retinal diseases.
Where can I find the Iridex financial results webcast?
The webcast for Iridex's financial results will be available on the "Event Calendar" page of their website.
What technology does Iridex use for eye treatments?
Iridex uses its proprietary MicroPulse® technology for safe and effective laser treatments for eye conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRIX Insider Trading Activity
$IRIX insiders have traded $IRIX stock on the open market 47 times in the past 6 months. Of those trades, 47 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IRIX stock by insiders over the last 6 months:
- WILLIAM M MOORE has made 9 purchases buying 107,500 shares for an estimated $113,016 and 0 sales.
- BEVERLY A HUSS purchased 25,900 shares for an estimated $31,499
- SCOTT SHUDA purchased 21,457 shares for an estimated $25,748
- ROMEO R DIZON (Chief Financial Officer) has made 32 purchases buying 15,245 shares for an estimated $17,497 and 0 sales.
- PATRICK MERCER (President and CEO) has made 4 purchases buying 7,796 shares for an estimated $9,997 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IRIX Hedge Fund Activity
We have seen 8 institutional investors add shares of $IRIX stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 70,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $69,300
- LONG FOCUS CAPITAL MANAGEMENT, LLC removed 38,173 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $37,791
- VANGUARD GROUP INC added 33,691 shares (+6.0%) to their portfolio in Q1 2025, for an estimated $33,354
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 30,869 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $30,560
- CONCURRENT INVESTMENT ADVISORS, LLC removed 21,944 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $19,352
- AMH EQUITY LTD added 17,420 shares (+3.5%) to their portfolio in Q1 2025, for an estimated $17,245
- TRUIST FINANCIAL CORP removed 12,979 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,849
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the second quarter 2025 and provide a business update after the close of trading on Tuesday, August 12, 2025.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing passcode : 2197032 followed by pressing #. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com .
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com .
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
[email protected]
